Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Completed · Phase 3 · NCT03183245
Conditions: Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
At a glance
- Research payments reported, 2025
- $211,814
- U.S. investigators named
- 22
- Sites paid
- 22
- Planned or actual enrollment
- 242
About the trial
- Sponsor
- Humacyte, Inc. (with CTI Clinical Trial and Consulting Services, California Institute for Regenerative Medicine (CIRM))
- Tested
- Human Acellular Vessel (HAV) (biological), Arteriovenous fistula (AVF) (procedure), Hemodialysis (other)
- Dates
- Started 2017-09-29; completion 2025-06-19
- Results posted
- Not yet
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
From ClinicalTrials.gov, last updated 2025-11-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Humacyte Global, Inc. reported $211,814 in research payments for this study in 2025 (42 payments).
Products named: Symvess
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony H. Chau, M.D. Vascular Surgery · Orange, CA
- Roy M. Fujitani, M.D. Vascular Surgery · Orange, CA
- Marquis E. Hart, M.D. General Surgery · San Diego, CA
- John S. Lane III, MD Vascular Surgery · San Diego, CA
- Mahmoud Malas, M.D. Vascular Surgery · La Jolla, CA
- Junichiro Sageshima, MD Transplant Surgery · Sacramento, CA
- Ernest E. Moore, MD General Surgery · Denver, CO
- Jonathan N. Bowman, M.D. Vascular Surgery · Darien, CT
- Ravi Rajani, M.D. General Surgery · Atlanta, GA
- Mark J. London, M.D. General Surgery · Chicago, IL
- Colby P. Atkins, M.D. General Surgery · Lexington, KY
- Damodar R. Kumbala, M.D. Nephrology (Kidney) · Baton Rouge, LA
- Alexander Kurbanov, MD General Surgery · West Springfield, MA
- C K. Ozaki, MD Vascular Surgery · Boston, MA
- Jason S. Burgess, MD General Surgery · Charlotte, NC
- David A. Peterson, MD Vascular Surgery · Angier, NC
- Joe T. Huang, M.D. Vascular Surgery · Newark, NJ
- Clifford M. Sales, MD Vascular Surgery · Westfield, NJ
- Gregory A. Magee, M.D. Vascular Surgery · New York, NY
- Teresa A. Crutchley, M.D. Vascular Surgery · Clackamas, OR
- Oscar H. Grandas, MD Vascular Surgery · Knoxville, TN
- Ruben D. Villa, M.D. Nephrology (Kidney) · Lubbock, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Southern California Institute for Research and Education $43,719
- Kidney Care & Transplant Services of New England $29,280
- Brigham and Women's Hospital, MA $20,558
- Indiana University Health, IN $15,437
- Uci Health-Orange, CA $11,226
- Denver Health & Hospital Authority, CO $11,004
- The Regents of the University of California $10,985
- University of California Davis Medical Center, CA $10,137
- United Surgical Associates $8,393
- Veterans Medical Research Foundation $7,937
- Frenova LLC $6,150
- Rutgers , the State University of New Jersey $5,395
- Musc Medical Center, SC $5,213
- Emory University Hospital, GA $5,160
- Morristown Medical Center, NJ $4,575
- University of Southern Californina $3,750
- Kaiser Foundation Hospital-Santa Clara, CA $3,300
- Vascular Breakthroughs LLC $3,250
- Surgical Specialist of Charlotte $2,287
- Lubbock Surgery Center $1,560
- University Health System, Inc, TN $1,500
- California Institue of Renal Research $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.